Insights from Therapeutic Studies for PrP Prion Disease

Cold Spring Harb Perspect Med. 2017 Mar 1;7(3):a024430. doi: 10.1101/cshperspect.a024430.

Abstract

Although an effective therapy for prion disease has not yet been established, many advances have been made toward understanding its pathogenesis, which has facilitated research into therapeutics for the disease. Several compounds, including flupirtine, quinacrine, pentosan polysulfate, and doxycycline, have recently been used on a trial basis for patients with prion disease. Concomitantly, several lead antiprion compounds, including compound B (compB), IND series, and anle138b, have been discovered. However, clinical trials are still far from yielding significantly beneficial results, and the findings of lead compound studies in animals have highlighted new challenges. These efforts have highlighted areas that need improvement or further exploration to achieve more effective therapies. In this work, we review recent advances in prion-related therapeutic research and discuss basic scientific issues to be resolved for meaningful medical intervention of prion disease.

Publication types

  • Historical Article
  • Review

MeSH terms

  • Aminopyridines / therapeutic use
  • Animals
  • Creutzfeldt-Jakob Syndrome / diagnosis*
  • Creutzfeldt-Jakob Syndrome / drug therapy*
  • Creutzfeldt-Jakob Syndrome / history*
  • Disease Models, Animal
  • Doxycycline / therapeutic use
  • Drug Discovery
  • History, 20th Century
  • History, 21st Century
  • Humans
  • Pentosan Sulfuric Polyester / therapeutic use
  • Quinacrine / therapeutic use
  • Randomized Controlled Trials as Topic
  • Translational Research, Biomedical

Substances

  • Aminopyridines
  • Pentosan Sulfuric Polyester
  • Quinacrine
  • flupirtine
  • Doxycycline